4 recruiting, 2 not yet recruiting. 3 Early Phase 1, 1 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 3 | Recruiting 2, Not yet recruiting 1 |
| Not applicable | 1 | Not yet recruiting 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow SSc-Systemic Sclerosis: new trials by email Literature Review of SSc-Systemic Sclerosis trials Research Report on SSc-Systemic Sclerosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Improving ILD Screening in Patients With RA and SSc Using EHR-Embedded CDS and PRO Tools EHR-Embedded CDS and PRO Tools Intervention - Rheumatoid Arthritis (RA), SSc-Systemic Sclerosis | Not applicable | Not yet recruiting | Foundation for Advancing Science Technology Education and Research | 800 | 2026-09-30 | 2026-09-30 |
| RD06-05 Universal CD19/BCMA CAR-T for Refractory Pediatric Autoimmune Diseases RD06-05 CART Cell Infusion - Autoimmune Diseases, SLE - Systemic Lupus Erythematosus | Early Phase 1 | Not yet recruiting | The Children's Hospital of Zhejiang University School of Medicine | 30 | 2026-07-01 | 2026-06-29 |
| Safety, Efficacy and Cellular Metabolic Dynamics of CT1195E in Patients With Refractory / Progressive SSC CAR-T Therapy - SSc-Systemic Sclerosis | Early Phase 1 | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 12 | 2026-01-16 | 2026-01-21 |
| CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases QT-019C - SLE - Systemic Lupus Erythematosus, SSc-Systemic Sclerosis | Phase 1 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 12 | 2026-01-01 | 2026-01-20 |
| A Study of CC312 for Relapsed/Refractory Autoimmune Diseases CC312 - SLE - Systemic Lupus Erythematosus, IIM- Idiopathic Inflammatory Myopathies | Early Phase 1 | Recruiting | CytoCares Inc | 6 | 2025-09-23 | 2026-04-14 |
| Double Immunosuppression With or Without Anti-fibrotic in Scleroderma ILD Antifibrotic drugs (nidanib or pirfenidone), MMF Immunosuppression - SSc-Systemic Sclerosis | Recruiting | University of Patras | 35 | 2025-06-01 | 2026-03-24 |
Lupus Erythematosus, Systemic (3) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (1) · Arthritis, Rheumatoid (1) · Autoimmune Diseases (1) · Glomerulonephritis, IGA (1) · Nephrotic Syndrome (1)
Connective Tissue Diseases (4) · Immune System Diseases (4) · Skin and Connective Tissue Diseases (4) · Autoimmune Diseases (3) · Arthritis (1) · Cardiovascular Diseases (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Glomerulonephritis (1) · Joint Diseases (1) · Kidney Diseases (1) · Male Urogenital Diseases (1) · Musculoskeletal Diseases (1) · Nephritis (1) · Nephrosis (1)
Immunotherapy, Adoptive (1) · Rituximab (1) · pirfenidone (1)
CytoCares Inc (1) · Foundation for Advancing Science Technology Education and Research (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · The Children's Hospital of Zhejiang University School of Medicine (1) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1) · University of Patras (1)
China (4) · Greece (1)
Jianhua Mao (1)